Abstract: An InGaN/GaN multiple quantum well blue light detector- includes: a Si substrate, an AlN/AlGaN/GaN buffer layer, a u-GaN/AlN/u-GaN/SiNx/u-GaN buffer layer, an n-GaN buffer layer, an InGaN/GaN superlattice layer and an InGaN/GaN multiple quantum well layer in sequence from bottom to top. The multiple quantum well layer has a groove and a mesa, the mesa and the groove of the multiple quantum well layer are provided with a Si3N4 passivation layer. The passivation layer in the groove is provided with a first metal layer electrode with a semicircular cross section, and the passivation layer on the mesa is provided with second metal layer electrode.

Abstract: A public event administrating system is disclosed. The public event involves a plurality of individuals and the administrating system includes: a data collecting module, a data processing module, a medical resource scheduling module, and a grid administrating module. The data collecting module is configured to acquire initial data about the public event from a plurality of data sources. The data processing module is configured to process the initial data to acquire processed data. The medical resource scheduling module is configured to receive an individual service request and allocate currently available medical resources to an individual requesting service at least according to the individual service request. And, the grid administrating module is configured to divide a geographic region managed by the administrating system into a plurality of grids, and assign a plurality of grid administrators to the plurality of grids to respectively administrate individuals in the plurality of grids.

Abstract: Disclosed is a novel compound and a process of preparing it. It has been shown to have anti-inflammatory activity and can be utilised in a wide range of cosmetic compositions. The compound is a 2(1H)-pyridinone of formula (1) in amide or enol form. It may be prepared by exposing a solution of piroctone olamine in an organic solvent or in water comprising at least one surfactant to UV radiation to degrade the piroctone olamine. The compound of formula (1) is separated from the degradation products by chromatography.

Abstract: Disclosed is a personal care composition comprising porous silica having an average diameter of 2 to 100 microns and lignin compound.

Abstract: A graph data processing method includes: acquiring target graph data to be processed; compiling statistics on the target graph data according to a first preset rule, so as to divide the target graph data into a plurality of graph data blocks and determine a boundary value and weight of each of the plurality of graph data blocks; and storing the boundary value and weight of each of the plurality of graph data blocks in a corresponding memory according to a second preset rule, so as to schedule the target graph data during a graph calculation process by use of the boundary values and the weights.

Abstract: An epitaxial structure of a nonpolar AlGaN-based deep-ultraviolet (DUV) photoelectric detector and a preparation method thereof are provided. The epitaxial structure of the nonpolar AlGaN-based DUV photoelectric detector includes a nonpolar AlN buffer layer, a nonpolar Al0.15Ga0.85N buffer layer, and a nonpolar Al0.7Ga0.3N epitaxial layer that are sequentially grown on a LaAlO3 substrate. The LaAlO3 substrate takes a (100) plane as an epitaxial plane, and AlN[11-20] as an epitaxial growth direction. With the LaAlO3 substrate, the epitaxial structure reduces dislocations and stresses between the substrate and the epitaxial buffer layer. By designing two AlGaN epitaxial buffer layers with different components, the epitaxial structure reduces a dislocation density and a surface roughness of the nonpolar AlGaN epitaxial layer, further accelerates photoresponse and detectivity of the detector, and enhances overall performance of the nonpolar AlGaN-based DUV photoelectric detector.

Abstract: A system (100) and a method for puncture path planning are provided. The system (100) comprises: at least one storage medium including a set of instructions; and one or more processors (210) communicating with the at least one storage medium. When executing the instructions, the one or more processors (210) are used to: determine a target point (410) based on a target image; determine one or more candidate paths (420) based on the target point and at least two constraints, wherein in the process of determining the one or more candidate paths, a path planning condition is adaptively adjusted based on a first preset condition; and determine a target path (430) based on the one or more candidate paths.

Abstract: An array substrate including a display area having a plurality of subpixels is provided. The plurality of subpixels includes a plurality of first subpixels in a display-bonding sub-area and a plurality of second subpixels in a regular display sub-area. The array substrate includes a plurality of thin film transistors on a first side of the base substrate and respectively in the plurality of subpixels. A respective one of the plurality of first subpixels includes a bonding pad on a second side of a base substrate; a lead line electrically connecting a respective one of a plurality of thin film transistors to the bonding pad; and a via extending through the base substrate. The lead line is unexposed in the array substrate. The lead line extends from the first side to the second side of the base substrate through the via, to connect to the bonding pad.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present disclosure relates to a display substrate, a display device, and a method for manufacturing a display substrate. The display substrate includes a base substrate having a first side and a second side opposite to the first side, a via provided in the base substrate, a thin film transistor provided on the first side of the base substrate, a first conductive structure provided on the first side of the base substrate, wherein a first sub-portion of the first conductive structure is located in the via, and wherein a material of the first conductive structure is the same as a material of a source/drain electrode of the thin film transistor.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: A coating for protecting a Zirconium alloy based layer of a nuclear fuel rod cladding is provided. The coating comprises a primary layer. A microstructure of the primary layer is comprised of a number of grains and is randomized. The primary layer is configured with a density of about 94.5% or greater. A cladding for a nuclear fuel rod and a method for producing a cladding for a nuclear fuel rod are also provided.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

Abstract: A detection result reading device is provided. The detection result reading device includes a reading device body. The reading device body is provided with a cavity at least capable of accommodating a detection part of a reagent card. A side wall of the cavity is provided with a detection result acquisition device, and the detection result acquisition device is arranged opposite to the detection part of the reagent card. The reading device body is provided with a lifting device for lifting the detection part of the reagent card towards a side of the cavity close to the detection result acquisition device.

Abstract: An auxiliary test paper detection device includes a reagent cap and a test paper cassette. The reagent cap contains a detection reagent, a sealing member is arranged at an opening of the reagent cap. The sealing member can be opened or removed under action of external force. Test paper is arranged in the test paper cassette, a sample absorption section of the test paper is exposed, an observation window is formed in the test paper cassette. A result display area of the test paper corresponds to the observation window. A connecting structure for connecting the test paper cassette and the reagent cap is provided, and when the test paper cassette and the reagent cap are connected through the connecting structure, a closed space is formed in an inner cavity of the reagent cap. The sample absorption section of the test paper extends into the inner cavity of the reagent cap.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).